Video
Dr. Peters Discusses Ongoing Research With Trastuzumab Deruxtecan in NSCLC
Author(s):
Solange Peters, MD, PhD, discusses ongoing research with fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) in patients with HER2-mutated non–small cell lung cancer.
Solange Peters, MD, PhD, chief, Medical Oncology Service, chair, Thoracic Oncology, Lausanne University Hospital, Lausanne, Switzerland, discusses ongoing research with fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) in patients with HER2-mutated non–small cell lung cancer (NSCLC).
Findings from the phase 2 DESTINY-Lung01 trial could provide the rationale that is needed to move trastuzumab deruxtecan into the first-line setting in this patient population, says Peters. Historically, EGFR and ALK inhibitors have demonstrated significantly improved progression-free survival when moved into the frontline setting, and the same could be true for trastuzumab deruxtecan.
Additionally, moving the therapy into the frontline setting may provide a more accurate representation of the associated toxicities, explains Peters. Treatments given in the second- and later-lines settings could display residual toxicities from earlier treatments, such as immunotherapy in this setting, concludes Peters.
